Abstract Submissions

Abstract submissions now open!

The Asia Pacific League of Associations for Rheumatology (APLAR) in conjunction with the Japan College of Rheumatology (JCR) invite you to submit an abstract for possible inclusion in the official congress program.

If accepted, your abstract will be published in an online supplement of International Journal of Rheumatic Diseases.

It is important that you read the submission guidelines before finalising your submission. Use the guidelines button to read more!

Abstract submission topics

Clinical rheumatology topics

Advances in pain management
Basic science related to rheumatic diseases
Behcet’s disease and miscellaneous rheumatic conditions
COVID-19
Epidemiology, COPCORD, health care system and pharmacoeconomics
Fibromyalgia
Genetics
Imaging techniques and diagnosis
Infection-related rheumatic diseases
Metabolic bone diseases and crystal-induced diseases
Osteoarthritis
Osteoporosis
Paediatric rheumatology
Psoriatic arthritis
Rehabilitation for rheumatic diseases
Rheumatoid arthritis anti-TNF therapy

Rheumatoid arthritis bDMARDs
Rheumatoid arthritis clinical aspects and co-morbidity
Rheumatoid arthritis csDMARDs
Rheumatoid arthritis non biological treatment
Rheumatoid arthritis non-TNF biological therapies
Rheumatoid arthritis prognosis, predictors and outcome
Rheumatoid arthritis tsDMARDs
Scleroderma, myositis and related syndromes
Soft tissue rheumatism
Spondylarthropathies biological and non-biological therapies
Spondylarthropathies clinical aspects and co-morbidity
Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome clinical aspects, comorbidities and complications
Systemic lupus erythematosus, Sjogrens and antiphospholipid syndrome therapies
Systemic vasculitis related to rheumatic diseases

Allied health research topics

Alternative medicine (e.g. acupuncture)
Case Report
COVID-19

Nursing
Physiotherapy
Psychological intervention and miscellaneous forms of care

All abstract submissions must be received electronically through the online submission portal. Use the submit now button to start your submission!

Submission terms and conditions

The APLAR 2021 terms and conditions and conditions of acceptance are included in the submission guidelines. It is important that you understand all of these conditions before submitting your abstract.

IMPORTANT dates

Please diarise the following important program dates.

Submission open – NOW!

Submission close – 2359 AEST, Friday 7 May 2021

Author notifications – Late June 2021

IMPORTANT LINKS

Have any questions?

If you have any questions regarding abstract submissions, please contact the APLAR Program Manager.

Janssen Pharmaceutical KK & Mitsubishi Tanabe Pharma Corporation

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Janssen Asia Pacific is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Asahi Kasei Pharma Corporation

Asahi Kasei Pharma discovers, develops, manufactures, and delivers prescription drugs in the fields of orthopedics, circulatory, urology, the immune system, and the central nervous system.

Pharmaceuticals from Asahi Kasei Pharma include Teribone™ for osteoporosis and Elcitonin™ Injection 20S for osteoporosis pain, the Recomodulin™ anticoagulant, each of which has a competitive position in its respective market.

Kevzara® is a human monoclonal antibody that blocks the action of interleukin-6 (IL-6) by binding to IL-6 receptors, for the indication of rheumatoid arthritis in patients who have had an inadequate response to conventional treatments.

Kevzara® is a registered trademark of Sanofi Biotechnology.

The product information is intended for general information purposes. The names, descriptions, and labeling of approved products are of Japan origin.

Product availability, names, indications, and presentations may vary from country to country.

Janssen, a division of Johnson & Johnson

Janssen Asia Pacific is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Eli Lilly Japan K.K.

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work.

Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow.

We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

Bristol Myers Squibb K.K.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Gilead Sciences K.K.

Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. Gilead’s Inflammation R&D team is focused on improving therapeutic options for the treatment of multiple inflammatory conditions through a comprehensive clinical trial program evaluating novel agents with the goal of advancing patient care.

Novartis Pharma K.K.

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. We consistently rank among the world’s top companies investing in research and development.

Pfizer. Japan Inc

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global health care portfolio includes human biologic and small molecule medicines and vaccines, as well as many of the world’s best-known consumer products.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Sales Operation Area Management Support, Japan Commercial, Astellas Pharma Inc.

Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of

19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: www.annualreport.boehringer-ingelheim.com.

Chugai Pharmaceutical Co., Ltd

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs.

Daiichi Sankyo Co., Ltd.

Glaxosmithkline

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

UCB Biopharma SRL

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines. Our ambition is to transform the lives of people living with severe diseases, with a focus in immunology and neurology.

Cesas Medical

The Cytokine Signalling Forum (CSF) is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.

Association of Women in Rheumatology

AWIR is a global organization with more than 11,000 touchpoints and 8 global chapters/partners worldwide. AWIR’s mission is to promote the science and practice of Rheumatology, foster the advancement and education of women in Rheumatology, and advocate access to the highest quality health care, and the management of patients with Rheumatic diseases.

LG Chem

LG Chem, the leading chemical company, has strengthened market dominance starting from the Basic Materials & Chemicals business to Energy Solution, IT and Electronic Materials and Life Science area.

Life Sciences Company focuses at four major healthcare services including pharmaceutical, vaccine, medical device and biopharmaceutical.

Based on its own fundamental technology, LG Chem expanded its pipeline to include biosimilars in order to improve patient access to highly effective biological products.

LG Chem will continue to improve the quality of life by providing innovative portfolio of medicines across the world.

Contact

Sponsor Name

Sponsor bio – Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Abstract Submissions

Abstract submissions now open!

Abstract submission topics

Submission terms and conditions

IMPORTANT dates

IMPORTANT LINKS

Have any questions?

#APLAR21

Janssen Pharmaceutical KK & Mitsubishi Tanabe Pharma Corporation

Asahi Kasei Pharma Corporation

Janssen, a division of Johnson & Johnson

Eli Lilly Japan K.K.

AbbVie

Bristol Myers Squibb K.K.

Gilead Sciences K.K.

Novartis Pharma K.K.

Pfizer. Japan Inc

Sales Operation Area Management Support, Japan Commercial, Astellas Pharma Inc.

Celltrion Healthcare

Contact

Boehringer Ingelheim

Chugai Pharmaceutical Co., Ltd

Daiichi Sankyo Co., Ltd.

Glaxosmithkline

UCB Biopharma SRL

Cesas Medical

Association of Women in Rheumatology

LG Chem

Contact

Sponsor Name

Contact